ANTIBIOTICE SA |
End-of-day quote
Other stock markets
|
||
| - RON | - |
|
| 06/06 | Antibiotice S.A. announced that it expects to receive $108.96 million in funding | CI |
| 15/05 | Antibiotice S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2022 | 497M 107M 8.94B | Sales 2023 | 615M 132M 11.07B | Capitalization | 937M 202M 16.84B |
|---|---|---|---|---|---|
| Net income 2022 | 38M 8.18M 683M | Net income 2023 | 81M 17.44M 1.46B | EV / Sales 2022 | 0.92 x |
| Net Debt 2022 | 79.25M 17.06M 1.43B | Net Debt 2023 | 64.49M 13.89M 1.16B | EV / Sales 2023 | 1.63 x |
| P/E ratio 2022 |
9.87
x | P/E ratio 2023 |
11.5
x | Employees | - |
| Yield 2022 |
1.4% | Yield 2023 |
3.3% | Free-Float | 17.57% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Ioan Nani
CEO | Chief Executive Officer | 64 | 01/87/01 |
| Director of Finance/CFO | 56 | 01/91/01 | |
Cornelia Moraru
CTO | Chief Tech/Sci/R&D Officer | 58 | 05/03/05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ioan Nani
CEO | Chief Executive Officer | 64 | 01/87/01 |
Mihai Trifu
BRD | Director/Board Member | 41 | 26/21/26 |
| Director/Board Member | 48 | 26/21/26 |
Antibiotice SA is a Romania-based company primarily active in the pharmaceutical industry. The Company manufactures drugs in five pharmaceutical forms: powder for injectable solutions and suspensions, capsules, tablets, suppositories and preparations. The Company's products are designed to treat a range of diseases, including infectious, dermatology, cardiovascular, digestive and musculoskeletal system related. The Company operates eight certified production lines. Its portfolio includes products for human and veterinary use, pharmaceutical ingredients and biological fertilizers. Additionally, the Company is engaged in the research and development activities.
Sector
Pharmaceuticals
Calendar
23/09/2024
- Détachement de for final dividend
| 1st Jan change | Capi. | |
|---|---|---|
| +41.10% | 630B | |
| -7.15% | 350B | |
| +18.77% | 328B | |
| +8.79% | 298B | |
| +17.51% | 246B | |
| -0.12% | 225B | |
| +10.40% | 218B | |
| +3.68% | 160B | |
| -4.38% | 156B |
